{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:11:14Z","timestamp":1790003474592,"version":"4.0.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.vph.2019.03.002","type":"journal-article","created":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T23:01:43Z","timestamp":1553295703000},"page":"8-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Treatment with PCSK9 inhibitors reduces atherogenic VLDL remnants in a real-world study"],"prefix":"10.1016","volume":"116","author":[{"given":"Tim","family":"Hollstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2094-1807","authenticated-orcid":false,"given":"Anja","family":"Vogt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Grenkowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Stojakovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfried","family":"M\u00e4rz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Laufs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bediha","family":"B\u00f6l\u00fckbasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Steinhagen-Thiessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Scharnagl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Kassner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vph.2019.03.002_bb0005","first-page":"115","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"70","author":"Catapano","year":"2017","journal-title":"Rev. Esp. Cardiol. (Engl Ed)"},{"key":"10.1016\/j.vph.2019.03.002_bb0010","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.vph.2019.03.002_bb0015","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1093\/eurheartj\/ehx549","article-title":"2017 update of ESC\/EAS task force on practical clinical guidance for proprotein convertase subtilisin\/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia","volume":"39","author":"Landmesser","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.vph.2019.03.002_bb0020","doi-asserted-by":"crossref","first-page":"III2","DOI":"10.1161\/01.CIR.0000131511.50734.44","article-title":"Atherogenic lipoprotein particles in atherosclerosis","volume":"109","author":"Carmena","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2019.03.002_bb0025","doi-asserted-by":"crossref","first-page":"1273042","DOI":"10.1155\/2017\/1273042","article-title":"Small dense low-density lipoprotein as biomarker for atherosclerotic diseases","volume":"2017","author":"Ivanova","year":"2017","journal-title":"Oxidative Med. Cell. Longev."},{"key":"10.1016\/j.vph.2019.03.002_bb0030","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1161\/ATVBAHA.114.305172","article-title":"Triglyceride-rich lipoproteins and coronary artery disease risk: new insights from human genetics","volume":"35","author":"Khetarpal","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.vph.2019.03.002_bb0035","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.atherosclerosis.2015.01.039","article-title":"New insights into the pathophysiology of dyslipidemia in type 2 diabetes","volume":"239","author":"Taskinen","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.vph.2019.03.002_bb0040","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.cocis.2005.11.006","article-title":"Lipoproteins: when size really matters","volume":"11","author":"German","year":"2006","journal-title":"Curr. Opin. Colloid Interface Sci."},{"key":"10.1016\/j.vph.2019.03.002_bb0045","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.atherosclerosis.2015.08.042","article-title":"A comparative study of four independent methods to measure LDL particle concentration","volume":"243","author":"Hopkins","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.vph.2019.03.002_bb0050","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s40256-016-0179-y","article-title":"LDL-cholesterol: standards of treatment 2016: a German perspective","volume":"16","author":"Marz","year":"2016","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"10.1016\/j.vph.2019.03.002_bb0055","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1093\/clinchem\/41.10.1414","article-title":"National Cholesterol Education Program recommendations for measurement of low-density lipoprotein cholesterol: executive summary. The National Cholesterol Education Program Working Group on Lipoprotein Measurement","volume":"41","author":"Bachorik","year":"1995","journal-title":"Clin. Chem."},{"key":"10.1016\/j.vph.2019.03.002_bb0060","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/ki.1991.92","article-title":"Effects of HMG-CoA reductase inhibitors in hypercholesterolemic patients on hemodialysis","volume":"39","author":"Wanner","year":"1991","journal-title":"Kidney Int."},{"key":"10.1016\/j.vph.2019.03.002_bb0065","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1080\/07315724.2007.10719582","article-title":"Modifications in postprandial triglyceride-rich lipoprotein composition and size after the intake of pomace olive oil","volume":"26","author":"Cabello-Moruno","year":"2007","journal-title":"J. Am. Coll. Nutr."},{"key":"10.1016\/j.vph.2019.03.002_bb0070","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.amjcard.2005.10.062","article-title":"Does low-density lipoprotein size add to atherogenic particle number in predicting the risk of fatal myocardial infarction?","volume":"97","author":"Jungner","year":"2006","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.vph.2019.03.002_bb0075","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1042\/CS20090402","article-title":"Regulation of plasma LDL: the apoB paradigm","volume":"118","author":"Sniderman","year":"2009","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.vph.2019.03.002_bb0080","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002224","article-title":"Effect of PCSK9 inhibition by alirocumab on lipoprotein particle concentrations determined by nuclear magnetic resonance spectroscopy","volume":"4","author":"Koren","year":"2015","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.vph.2019.03.002_bb0085","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.amjcard.2017.10.028","article-title":"Effect of evolocumab on lipoprotein particles","volume":"121","author":"Toth","year":"2018","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.vph.2019.03.002_bb0090","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.116.025080","article-title":"PH RB: Factorial effects of evolocumab and atorvastatin on lipoprotein metabolism","volume":"135","author":"Watts","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2019.03.002_bb0095","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.116.025253","article-title":"Effects of PCSK9 inhibition with alirocumab on lipoprotein metabolism in healthy humans","volume":"135","author":"Reyes-Soffer","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2019.03.002_bb0100","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1161\/01.ATV.16.1.149","article-title":"Plasma concentration of apolipoprotein E in intermediate-sized remnant-like lipoproteins in normolipidemic and hyperlipidemic subjects","volume":"16","author":"Cohn","year":"1996","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.vph.2019.03.002_bb0105","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1161\/01.ATV.19.3.472","article-title":"Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3","volume":"19","author":"Jong","year":"1999","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.vph.2019.03.002_bb0110","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11789-017-0085-0","article-title":"PCSK9 targets important for lipid metabolism","volume":"12","author":"Schulz","year":"2017","journal-title":"Clin. Res. Cardiol. Suppl."},{"key":"10.1016\/j.vph.2019.03.002_bb0115","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.atherosclerosis.2014.07.008","article-title":"Very low density lipoprotein cholesterol associates with coronary artery calcification in type 2 diabetes beyond circulating levels of triglycerides","volume":"236","author":"Prenner","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.vph.2019.03.002_bb0120","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12944-016-0197-4","article-title":"Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: analysis of 3 randomized trials versus placebo","volume":"15","author":"Toth","year":"2016","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.vph.2019.03.002_bb0125","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Investigators: evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2019.03.002_bb0130","doi-asserted-by":"crossref","first-page":"45788","DOI":"10.1038\/srep45788","article-title":"Efficacy of alirocumab according to background statin type and dose: pooled analysis of 8 ODYSSEY phase 3 clinical trials","volume":"7","author":"Catapano","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.vph.2019.03.002_bb0135","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.005367","article-title":"Systematic review and network meta-analysis on the efficacy of evolocumab and other therapies for the management of lipid levels in hyperlipidemia","volume":"6","author":"Toth","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.vph.2019.03.002_bb0140","doi-asserted-by":"crossref","first-page":"I7","DOI":"10.1002\/clc.4960261304","article-title":"New dimension of statin action on ApoB atherogenicity","volume":"26","author":"Chapman","year":"2003","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.vph.2019.03.002_bb0145","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1476-511X-7-22","article-title":"Plasma PCSK9 levels are significantly modified by statins and fibrates in humans","volume":"7","author":"Mayne","year":"2008","journal-title":"Lipids Health Dis."},{"issue":"4","key":"10.1016\/j.vph.2019.03.002_bb2000","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1074\/jbc.M708098200","article-title":"The Proprotein Convertase PCSK9 Induces the Degradation of Low Density Lipoprotein Receptor (LDLR) and Its Closest Family Members VLDLR and ApoER2","volume":"283","author":"Poirier","year":"2008","journal-title":"J. Biol. Chem."}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189118304385?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189118304385?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T01:17:52Z","timestamp":1761527872000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189118304385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":30,"alternative-id":["S1537189118304385"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2019.03.002","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment with PCSK9 inhibitors reduces atherogenic VLDL remnants in a real-world study","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2019.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}